Εκπαιδευτικά προγράμματα
Λίστα αντικειμένων

We
reviewed a case of AML with 11q23 abnormality involving the MLL
gene and discussed the indication for transplant.
Presenter: Prof. Spyridondis
Particiaptns: Dr Liga, Dr Spyridis, Dr Lekka, Dr Bountouris


We presented a retrospective study showing that from patients
not
receiveing alllo-HCT at CR-1, at 10 years 16.6% of patients aged
<60
years and 2.4% of those aged ≥60 years were alive and disease-free.
This
disease-free AML group consisted predominantly of patients
with
core-binding factor AML with t(8;21)(q22;q22)
or
inv(16)(p13q22)/t(16;16)(p13;q22)
and...


Human herpesvirus 6 as a possible cause of pleuropericardial
effusion in patients with hematologic malignacies after allogeneic
transplantation.
Presenter: Dr Lekka
Participants: Prof.Spyridonidis, Dr Liga, Dr Spyridis, Dr
Bountouris


The study from the French group with positive results in gene
therapy for Transfusion dependent Thalassemia patients was
presented. We discussed the ended of conditioning in these patients
with busulphan. Furthermore we discussed the need of busulphan
levels in specific patients (eg children, thalssemia...


We discussed a case of isolated CNS relapse of an ALL ph + after
BMT.
Interestingly the CNS relapse revealed with an AML clone. We
discussed
the current literature.
We specifically reviewed the cases in Table 3 of the paper
attached.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr...


Revised diagnosis and severity criteria for sinusoidal obstruction
syndrome/veno-occlusive disease in adult patients: a new
classification from the European Society for Blood and Marrow
Transplantation
Presenter: Dr Spyridis
Participants: Prof.Spyridonidis, Dr Liga, Dr Lekka, Dr
Bountouris


If uncommon haplotype then a MUD search may be
commited.
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr
Bountouris


A patient of ours with hhv6 viremia reveled pleuritis and
pericardial infusion. Dr Lekka reviewed the literature and
presented two case reports with hhv6 associated
pericarditis.
Presenter: Dr Lekka
Participants: Prof.Spyridonidis, Dr Liga, Dr Spyridis, Dr
Bountouris


Έγινε παρουσίαση της Δημοσίευσης της εγκριτικής μελέτης του EPREX
στο Leukemia 2018 και συζητηθηκε ο αλγοριθμος θεραπειας στα MDS low
risk.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Aggelinas


Two retrospective studies from EBMT and CIBMTR verified
that
conditioning intensity plays a role in BMT for AML. We discussed
the
terms myeloablative, RIC, RTC, NMA, lymphodepleting. Dr.
Spyridonidis
presented his new (EBMT) intensity index.
Presenter: Prof. Spyridondis
Participants: Dr Liga, Dr Spyridis, Dr Aggelinas


The antiviral prophylaxis for cytomegalovirus infection in
allogeneic
hematopoietic cell transplantation was reviewed. Prophylaxis reduse
CMV
reactivation and disease but has little effect on OS in older
studies,
except the newly published letermovir study.
We discussed our current practice.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Aggelinas


A transplantational research project showing that the combined Tx
of CBU and
multiple allogeneic progenitors may facilitate early engraftment
without
affecting the long term engraftment of the single CBU.
Presenter:Prof.Spyridonidis
Participants: Dr.Liga, Dr.Spyridis, Dr.Aggelinas


We discussed an excellent article published in NEJM regarding the
clinical value of PDL1 expression.
Presenter:Prof.Spyridonidis
Participants: Dr.Liga, Dr.Spyridis, Dr.Aggelinas


The significance of HHV6 viremia was discussed.
Presenter:Prof.Spyridonidis
Participants:Dr.Liga, Dr.Spyridis, Dr.Aggelinas


A study entitled "Graft-versus-host disease in recipients of
male
unrelated donor compared with parous female sibling donor
transplants"
was presented.
This was a retrospective cohort study in adults with acute
myeloid
leukemia, acute lymphoblastic leukemia, or myelodysplastic
syndrome, who
underwent T-cell replete HCT from these 2 donor types (parous
female
sibling...


A retrospective study comparing sibling vs PTCY haplo was
presented
Patient age, 18 to 54 years: comparable survival after transplants
from
an HLA-matched sibling and a haploidentical
sibling.
Patient age, 55 to 76 years: better survival after transplants from
an
HLA-matched sibling compared with offspring.
Presenter: Prof.Spyridonidis
Participants: Dr.Liga, Dr.Spyridis,...


The use of defibrotide in blood and marrow transplantation was
discussed.
Presenter: Prof. Spyridonidis
Participants: Dr.Liga, Dr.Spyridis, Dr.Aggelinas


A paper in BV entitled "Prediction of cardiovascular disease
among
hematopoietic cell transplantation survivors" was
presented.
Presenter: Prof. Spyridonidis
Participants: Dr.Liga, Dr Spyridis, Dr. Aggelinas


Based on a case of our unit we discussed "Outcomes of patients
who
developed subsequent solid cancer after hematopoietic
cell
transplantation"
Presenter:Prof.Spyridonidis
Participants:Dr.Liga, Dr.Spyridis, Dr.Aggelinas


A paper published in Blood Advances and entitled "How ibrutinib,
a
B-cell malignancy drug, became an FDA-approved second-line therapy
for
steroid-resistant chronic GVHD" was presented.
Presenter:Prof.Spyridonidis
Participants:Dr Liga, Dr Spyridis, Dr Aggelinas


